80 results about "Antigen presentation" patented technology

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention discloses a method for preparing a multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method, and relates to a preparation method of a nano-hydroxyapatite-based tumor vaccine. The invention aims to solve the problems of low antigen presentation efficiency of existing tumor vaccines and complex preparation process of nano vaccines based on tumor cell membranes. The preparation method comprises the following steps: 1, preparing small-particle-size calcium-based nanoparticles; and 2, synthesizing the HAP NV (at) DOX nano compound. The preparation method is used for preparing the multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method.

The application provides a kind of HLA-A24:02 APC cell preparation method and application, it is related to cell preparation technical field.The present application constructs the APC cell (K562-HLA-A24:02) that can replace HLA-A24:02 subtype DC cell, fills the blank of HLA-A24:02 subtype special engineering APC cell, and the cell can realize the antigen presentation function consistent with natural HLA-A24:02 subtype DC cell, provides special tool cell for the immune research for the HLA subtype;The present application constructs APC cell with K562 cell line as base, K562 cell can be in vitro permanent passage amplification, without repeatedly separating and inducing DC cell from human peripheral blood, reduces the use amount of peripheral blood, reduces the raw material dependence and cost of cell acquisition, while avoiding the influence of individual difference of peripheral blood source on experimental results.

Abstract Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell. Abstract 2018 / 22761 oM - cell Target ml Target cell cell cell Target Target Target SUBSTITUTE SHEET (RULE 26) cell cell cell Target Target cell cell 1 / 28 my Isolate recognized cell Library of target cells target cells and displaying different Add T cells from sample sequence antigens antigens of interest. CTLs deliver cytotoxic granules to target cells displaying cognate antigen FIG. 1 PCT / US2018 / 036663 20 26 20 53 56 07 J ul 2 02 6 2 0 2 6 2 0 5 3 5 6 0 7 J u l 2 0 2 6 2 0 1 8 / 2 2 7 6 1 o M a n d m y 1 / 2 8 m y L i b r a r y o f t a r g e t c e l l s d i s p l a y i n g d i f f e r e n tA d d T c e l l s f r o m s a m p l e of interest. CTLs deliver c y t o t o x i c g r a n u l e s t o t a r g e t c e l l s d i s p l a y i n g c o g n a t e a n t i g e n P C T / U S 2 0 1 8 / 0 3 6 6 6 3

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

The application relates to an aptamer-membrane fusion liposome nanomedicine as well as a preparation method and application thereof, and belongs to the technical field of nanomedicine preparation. The aptamer-membrane fusion liposome nanomedicine disclosed by the application is formed based on the affinity between the cholesterol (Chol) at the 3' end of an aptamer and a liposome, has small bond energy, good spatial orientation, high selectivity and reversibility. In the aptamer-membrane fusion liposome nanomedicine, the liposome can be fused with a membrane, co-loaded auranofin (AUR) has the functions of promoting cell iron death and sensitizing radiotherapy, the immunoadjuvant aptCpG can target dendritic cells (DCs), stimulate the functions of DCs maturation and antigen presentation, and further activate subsequent immune responses. The bionic liposome nanomedicine provides a new way for improving the effectiveness of clinical malignant tumor treatment.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The invention relates to the field of immune cells. According to the preparation method and application of the novel immune cell, lentivirus containing DNA molecules subjected to gene modification is used for transfecting cells in peripheral blood of mammals, so that the cells can be passaged for multiple times, and the cells have the antigen presenting capacity and the capacity of activating and amplifying natural killer cells. After the cell is further genetically modified, better transmembrane transfer, antigen presentation and natural killer cell activation can be realized. After gene modification, the cell and different cytokines or small molecules jointly activate and amplify mononuclear cells to obtain a larger number of natural killer cells with higher purity, epigenetics are regulated and controlled to change the receptor and ligand expression quantity of the natural killer cells, and then the cytotoxicity of effector cells is improved. The invention can be used for preparing antigen presenting cells and CTL cells aiming at different antigens and an application method. The cells and the using method have wide application prospects in the aspects of prevention and treatment of tumors and infectious diseases.

The invention discloses a cGAS-STING pathway activated tumor vaccine based on X-type framework nucleic acid, and belongs to the technical field of biological medicine and immune engineering. The vaccine is composed of X-type framework nucleic acid and alkynyl modified antigen peptide, the X-type framework nucleic acid is of a four-arm Halide knot structure formed by self-assembly of four oligonucleotide chains, and the antigen peptide is coupled to the oligonucleotide chains. According to the invention, the unique multi-branch topological structure of the X-type framework nucleic acid is utilized to enhance the binding stability with cGAS and efficiently activate a cGAS-STING signal channel without additional adjuvants; meanwhile, stable presentation and efficient delivery of the antigen peptide are realized, dendritic cell maturation and antigen presentation are promoted, and strong antigen specific CD8 + T cell immune response is induced. The vaccine shows a remarkable tumor inhibition effect in tumor prevention and treatment models, has the advantages of stable structure, high immunization efficiency, good safety and the like, and provides a novel vaccine platform for tumor immunotherapy.

The application discloses a CD40L-IL-2 fusion protein and a preparation method and application thereof in preparing a tumor treatment drug. The fusion protein comprises a CD40L trimer or a variant thereof and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers connected. The fusion protein provided by the application can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing, forms a closed-loop anti-tumor immune response of 'antigen presentation-immune initiation-effect amplification', and provides an effective strategy for treating tumors.

The present disclosure provides a training method of an antigen presentation prediction model and a prediction method, device and medium thereof, the training method comprising: obtaining antigen sequence training data and presentation probability training data for characterizing the presentation probability of the antigen sequence; inputting the antigen sequence training data into the antigen presentation prediction model to be trained; performing presentation prediction processing on the antigen sequence training data by the antigen presentation prediction model to predict the presentation probability corresponding to the antigen sequence training data, wherein the antigen sequence training data is subjected to amino acid encoding and vector mapping processing by a feature encoding module of the antigen presentation prediction model; and training the antigen presentation prediction model according to the predicted presentation probability and the presentation probability training data. The present disclosure effectively establishes a neural network algorithm model based on antigen sequence by using deep learning technology, effectively solves the problem of poor prediction of new antigen presentation ability, and improves the accuracy and efficiency of predicting antigen presentation ability.

The present application relates to the technical field of bioengineering, and particularly relates to a pIX region antigen-carrying capsid armed adenovirus, a construction method and application. An exogenous antigen gene is introduced into a pIX region of a minor capsid protein of a type 5 adenovirus to form a capsid armed adenovirus; the type 5 adenovirus specifically has an E1 region and an E3 region deletion. The construction method uses pIX as a display platform, can present an exogenous antigen on the virus surface with high density and high repeatability, greatly improves the effective concentration of the antigen, and is expected to induce stronger and more persistent specific immune responses; the modified pIX protein has less influence on the packaging, assembly, structural stability of the virus and the infection ability on target cells; the adenovirus can realize the dual functions of "gene delivery" and "surface antigen presentation", and provides an innovative technical platform for developing multifunctional and high-titer vaccines or gene therapy drugs.

This invention discloses a method for inducing B-CD4 + Freeze-dried tumor tissue with T-cell interaction, its preparation method, and its applications. This study aims to address the lack of effective treatments for postoperative recurrence of microsatellite stable (MSS) solid tumors, the easy degradation and inactivation of traditional autologous whole antigen vaccines, insufficient presentation efficiency, and the limitation of only activating classical CD8. + The core bottleneck of the T cell pathway. This invention utilizes vacuum freeze-drying technology to prepare porous, degradable freeze-dried tumor tissue (LT) from clinically derived or artificially cultured tumor tissue. This process fully preserves the tumor's complete antigen spectrum, tumor-specific antigens, and the immunogenicity of related antigens. It allows for highly efficient antigen presentation via dendritic cells, specifically inducing B cells and CD4+. + T-cell interaction mediates non-classical anti-tumor immunity that does not rely on traditional cytotoxic immune cells, significantly inhibiting the growth of residual lesions after solid tumor surgery. It has both broad-spectrum anti-cancer effects and excellent biosafety, and is especially suitable for postoperative adjuvant immunotherapy for MSS-type colorectal cancer.

The application belongs to the technical field of animal vaccines, and particularly relates to an O-A-Dex-Ap for African swine fever immunization. Based on the good biocompatibility of Dextran, the application uses the Dextran as a nanoparticle to load a coupled CTL epitope peptide. Preliminary experimental results show that, compared with the epitope peptide alone, the O-A-Dex-Ap after loading and coupling can more effectively promote antigen presentation and activate more persistent CTL immune response, and has good application potential. Based on the results, a good technical foundation can be laid for subsequent preparation of African swine fever and other disease vaccines.

The application provides an immunogenic epitope prediction method based on antigen presentation and immunogenicity feature fusion, comprising the following steps: extracting peptide segments and type I human leukocyte antigen protein features from an immunogenic epitope database by using a constructed feature extraction module; inputting the peptide segments and type I human leukocyte antigen protein features into a pre-trained antigen presentation prediction model to obtain an antigen presentation probability based on the antigen presentation prediction model; inputting the peptide segments, type I human leukocyte antigen protein features and antigen presentation probability information into an immunogenicity prediction model to realize fusion of antigen presentation and immunogenicity features, and obtaining an immunogenicity score representing a T cell activation probability of the peptide segments based on the immunogenicity prediction model, so as to realize prediction of the immunogenic epitope. The application improves the prediction accuracy of the immunogenic epitope.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

A method for increasing the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.

The invention provides a dendritic cell vaccine for treating bone and soft tissue sarcoma as well as a preparation method and application of the dendritic cell vaccine. The dendritic cell vaccine comprises mature dendritic cells obtained by co-culturing sarcoma cell lysate and immature dendritic cells. The lysates of seven sarcoma cells are used as dendritic cell vaccine antigens, the problem that an existing DC vaccine is single in loaded antigen is solved, antigen presentation and T cell activation are enhanced, wide immune response is excited, immune escape is reduced, and the dendritic cell vaccine is not limited by the type of MHC of a patient, is high in universality and can benefit more patients.

Provided herein are chimeric antigen receptors, comprising an extracellular domain capable of binding to an antigen, an Fc region, a flexible linker, a transmembrane domain, and may further comprise at least one intracellular domain that is designed to increase the anti-tumor activities of granulocytes, macrophages, and dendritic cells by increasing their phagocytosis and / or proinflammatory cytokines secretion and / or antigen presentation. Provided herein are vectors and nucleic acid molecules encoding any of the chimeric antigen receptors described herein. Provided herein are methods to genetically engineer granulocyte-macrophage progenitors (GMPs) to express the chimeric antigen receptors described herein. The CAR-Fc-GMPs may be induced to differentiate into macrophages or granulocytes. Provided herein are macrophages and granulocytes that express a CAR-Fc prepared by any of the methods described herein. Provided herein is an immunotherapy method for treating a subject having cancer with GMPs or macrophages or granulocytes that express the chimeric antigen receptors described herein.

The invention discloses a bladder cancer combined treatment method based on CTSE enhancement. According to the application, research finds that CTSE is a key factor related to ICB reaction and patient survival rate improvement. Functional studies find that CTSE improves the curative effect of ICB by enhancing MHC expression, so that antigen presentation, T cell activation and anti-tumor immunity are promoted, and the anti-inflammatory phenotype of macrophages is adjusted at the same time. Importantly, overexpression of the CTSE can further enhance the immunoreaction for blocking the PD-1, has the effect of synergistically treating the bladder cancer, and provides a new idea for effective treatment of the bladder cancer.

The present application discloses PLPC-DB, an ultrapurified phospholipoproteomic composition derived from the supernatant of peripheral blood mononuclear cells (PBMCs). It comprises essential phospholipids, bioactive proteins, regulatory peptides, and intercellular signaling factors. The composition exceeds 99% purity through a multi-stage purification process combining high-speed centrifugation and selective ultrafiltration (1-50 kDa), followed by lyophilization. This process ensures structural stability for ≥24 months and inter-batch variability <2%. PLPC-DB supports reproducibility and molecular integrity in research and diagnostic settings. Key components include phosphatidylcholine and phosphatidylserine for membrane stabilization and intracellular signaling; structural and regulatory lipids for membrane biogenesis and immune-relevant components involved in antigen presentation, cytokine modulation, and membrane-associated signaling. These may include structurally defined molecules compatible with immunological evaluation in experimental and non-therapeutic settings. The composition is formulated for bioaccessible delivery via sublingual, endonasal, transdermal, and injectable routes, and is intended exclusively for non-therapeutic use in experimental and translational models.

The invention belongs to the technical field of biological medicine, and particularly relates to a co-load bionic whole-tumor vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing fungal cell wall nanoparticles, preparing dead tumor cells and synthesizing the coupled vaccine. The invention discloses a co-load bionic whole-tumor vaccine, which breaks through the expression limitation of natural antigens, and enhances an immunogenicity activation signal through artificial modification. Immune cells are activated in a targeted manner through fungal cell wall components, so that the antigen presentation efficiency is remarkably improved. The compound can be applied to preparation of medicines for preventing and treating tumor diseases or medicines for inhibiting tumor recurrence or metastasis. The invention also discloses a preparation method of the co-loaded bionic whole-tumor vaccine, the preparation process is simplified, and the process complexity is reduced by using a standardized coupling technology of microorganisms and tumor cells.

The application provides an in-situ injectable mRNA-hydrogel microsphere complex, a preparation method and application thereof, and belongs to the technical field of biological medicine. The application constructs an injectable mRNA / sgRNA lipid nanoparticle-gel micro-complex, which is used for functionally reprogramming immune-suppressed macrophages in situ at a lesion, and aims to simultaneously strengthen the bactericidal capacity and restore the immune activation function. The encapsulation of the hydrogel microspheres makes the LNP stably stay at the lesion site, and the released phosphatidylserine modified LNP can realize selective delivery to macrophages through TAM receptors. The knockout of MerTK enhances the phagocytic capacity of macrophages and activates the pro-inflammatory signaling pathway, and the delivery of LL-37 mRNA realizes the continuous secretion of antibacterial peptides, thereby significantly enhancing the bactericidal effect. The in-vitro and in-vivo experimental results show that the LMP can realize precise positioning expression at the lesion site, significantly enhance the phagocytic activity, intracellular clearance capacity and antigen presentation function of macrophages, thereby overall inhibiting the progress of implant-related infection.

The invention relates to the technical field of anti-breast cancer tumor drugs, in particular to application of Rab001 combined with a PD-1 monoclonal antibody in preparation of anti-breast cancer tumor drugs. The invention discloses an application of Rab001 combined with a PD-1 monoclonal antibody in preparation of an anti-breast cancer tumor drug, the Rab001 promotes antigen presentation, antibody generation, formation of a tertiary lymphatic structure (TLS) and regulation of a tumor microenvironment by increasing the number and activity of peripheral circulating B lymphocytes and M1 type macrophages, M1 / M2, CD8 + T and B cells in tumors, so that the treatment effect of the PD-1 monoclonal antibody is enhanced.

The present application belongs to the technical field of biological medicine, and particularly relates to a method for predicting the in-vitro immunogenicity of biological drugs based on co-culture of dendritic cells and T cells. The present application constructs an in-vitro immunogenicity evaluation method with immature dendritic cells as the core. By limiting the dendritic cell differentiation time, not introducing any maturation stimulating factors, and removing free drug molecules after antigen treatment and then co-culturing with T cells, the T cell activation is mainly derived from the antigen presentation process itself, thereby effectively reducing the interference of drug pharmacological action or non-specific immune activation on the detection results. At the same time, the present application discards the traditional detection method relying on T cell proliferation or cytokine release, and adopts the early activation state of T cells as the evaluation index, thereby reducing the experimental complexity, shortening the experimental period, and solving the technical problem that the specificity is insufficient and the experimental period is too long to be considered in the existing in-vitro immunogenicity evaluation method.